After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...
Shares of Hims & Hers Health tumbled 18% premarket on Tuesday as Wall Street analysts questioned the telehealth provider's ...
Revenue was in line with analyst estimates. Earnings per share (EPS) was also in line with analyst expectations. Looking ...
Hims & Hers stock tumbled after the company confirmed it would stop selling some compounded weight-loss drugs.
Hims & Hers said on Monday that it may no longer be able to sell compounded versions of the weight-loss drug made by Novo ...
Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...
Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s ...
Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25 ...
Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...
Hims & Hers Health shares were headed for their biggest single-day plunge as Wall Street analysts questioned the telehealth ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback